Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
measles, mumps, and rubella vaccine (GSK)
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular
01
Overview
The measles, mumps, and rubella (MMR) vaccine is a live attenuated combination vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older. It contains weakened strains of the measles virus (e.g., Schwarz or Edmonston-Enders), mumps virus (e.g., RIT 4385 or Jeryl Lynn), and rubella virus (RA 27/3). The vaccine works by inducing a humoral and cellular immune response, leading to the production of protective antibodies against all three pathogens. Major commercial products include GSK's Priorix and Merck's M-M-R II, which are considered interchangeable in many clinical settings. It is typically administered as a two-dose series.
- Brand names
- PriorixM-M-R II
- Other names
- MMR vaccinemeasles, mumps, and rubella vaccine, live
02
Targets
SLAMF1 (SLAM family member 1)SA (Sialic acid)MOG (Myelin oligodendrocyte glycoprotein)Viral RNA-sensing pattern recognition receptorsT-cell receptor specific for measles, mumps, and rubella peptide–MHC complexesPVRL4 (Nectin cell adhesion molecule 4)CD46 (CD46 Molecule)B-cell receptor specific for measles, mumps, and rubella viral antigens
Beyond the preview
Go deeper on measles, mumps, and rubella vaccine (GSK).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on measles, mumps, and rubella vaccine (GSK).